Accueil>>UPGL00004

UPGL00004

Catalog No.GC61365

UPGL00004 est un puissant inhibiteur allostérique de la glutaminase C (GAC) (IC50 = 29 nM ; Kd = 27 nM). UPGL00004 inhibe fortement la prolifération des lignées cellulaires de cancer du sein triple négatif très agressives.

Products are for research use only. Not for human use. We do not sell to patients.

UPGL00004 Chemical Structure

Cas No.: 1890169-95-5

Taille Prix Stock Qté
10mM (in 1mL DMSO)
95,00 $US
En stock
5mg
81,00 $US
En stock
10mg
144,00 $US
En stock
50mg
495,00 $US
En stock
100mg
855,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC50=29 nM; Kd=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines[1].

UPGL00004 inhibits MDA-MB-231, HS578T and TSE cells with IC50s of 70, 129, and 262 nM, respectively[1].

The combination of UPGL00004 (1 mg/kg body weight) and Bevacizumab (2.5 mg/kg body weight) via intraperitoneal injection completely prevent any detectable increase in tumor size in a triple-negative breast cancer patient-derived tumor graft model[1].

[1]. Huang Q, et al. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J Biol Chem. 2018 Mar 9;293(10):3535-3545.

Avis

Review for UPGL00004

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for UPGL00004

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.